Feb. 2025

In February 2025, a patient with non-small cell lung cancer (NSCLC) enrolled in Qurgen’s US Phase 1 clinical trial achieved a complete response (CR) after received SON-DP treatment for three months. As of July 2026, a 18-month follow-up demonstrated that the patient remained tumor-free status.